Formulation: A solid
Formal Name: (2R,3R,4S,5S,6R)-3,5-dihydroxy-2-(((2S,3R,E)-3-hydroxy-2-(octadecanamido-18,18,18-d3)octadec-4-en-1-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl hydrogen sulfate
Purity: ≥99% deuterated forms (d1-d3)
Formula Markup: C42H78D3NO11S
Formula Weight: 811,2
Shelf life (days): 1460
Notes: C18 3'-sulfo Galactosylceramide-d3 (d18:1/18:0-d3) is intended for use as an internal standard for the quantification of C18 3'-sulfo galactosylceramide (Item No. 24863) by GC- or LC-MS. C18 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. It is a minor endogenous sphingolipid produced from C18 ceramide (Item No. 19556) and UDP-galactose in the endoplasmic reticulum followed by sulfation in the Golgi apparatus.{40646} C18 3'-sulfo Galactosylceramide levels are increased in brain tissue isolated from mice with an arylsulfatase A deficiency (ASA-KO), particularly in lipid raft fractions.{43012,36639} Plasma levels of C18 3’-sulfo galactosylceramide positively correlate with disability progression in patients with relapsing-remitting multiple sclerosis using the Expanded Disability Status Scale.{36640} It is also increased in plasma from patients with metachromatic leukodystrophy (MLD).{40650} Brain levels of short-chain sulfatides, including C18 3’-sulfo galactosylceramide, decrease with age in mice and humans.{43012,40648} As this product is derived from a natural source, there may be variations in the sphingoid backbone. [Matreya, LLC. Catalog No. 1536]
English
Deutsch
